Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nighat, Mehdi"'
Autor:
Ahmet Z Uluer, Gordon MacGregor, Pilar Azevedo, Veronica Indihar, Claire Keating, Marcus A Mall, Edward F McKone, Bonnie W Ramsey, Steven M Rowe, Ronald C Rubenstein, Jennifer L Taylor-Cousar, Elizabeth Tullis, Lael M Yonker, Chenghao Chu, Anna P Lam, Nitin Nair, Patrick R Sosnay, Simon Tian, Fredrick Van Goor, Lakshmi Viswanathan, David Waltz, Linda T Wang, Yingmei Xi, Joanne Billings, Alexander Horsley, Edward F. Nash, Marleen Bakker, Renske van der Meer, Petrus Merkus, Christof Majoor, Karen McCoy, Krishna Pancham, James Tolle, Bryon Quick, Ahmet Uluer, Emily DiMango, Adupa Rao, Santiago Reyes, Ross Klingsberg, Celeste Barreto, Victor Ortega, Donna Willey-Courand, Carsten Schwarz, Sivagurunathan Sutharsan, Rainald Fischer, Jane Davies, Jamie Duckers, Simon Doe, Harry Heijerman, George M. Solomon, Christian Merlo, Jennifer Griffonnet, Joseph Pilewski, Jordan Dunitz, Saba Sheikh, Ronald C. Rubenstein, Daniel B. Rosenbluth, Theodore Liou, Maria Indihar, Lael Yonker, Samya Nasr, Cynthia D. Brown, Gregory S. Sawicki, Jennifer Ruddy, Bryan Garcia, Andrew Braun, Alex H. Gifford, Nighat Mehdi, Maria Tupayachi Ortiz, Raksha Jain, Francisco J. Calimano, Jimmy Johannes, Cori L. Daines, Jason Fullmer, Joel Mermis, Christopher Barrios, Ngoc Ly, Brian P. Casserly, Stephan Eisenmann, Helge Hebestreit, Alexander Kiefer, Daniel Peckham, Martin Ledson, Eva Van Braeckel, Noel Gerard McElvaney, Edward McKone, Barry Plant, Lucy Burr, Daniel J. Smith, Peter Middleton, John Wilson
Publikováno v:
The Lancet Respiratory Medicine, 11(6), 550-562. Elsevier Limited
VX18-121-101 & VX18-561-101 Study Groups 2023, ' Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis : randomised, double-blind, controlled, phase 2 trials ', The Lancet Respiratory Medicine, vol. 11, no. 6, pp. 550-562 . https://doi.org/10.1016/S2213-2600(22)00504-5
LANCET RESPIRATORY MEDICINE
VX18-121-101 & VX18-561-101 Study Groups 2023, ' Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis : randomised, double-blind, controlled, phase 2 trials ', The Lancet Respiratory Medicine, vol. 11, no. 6, pp. 550-562 . https://doi.org/10.1016/S2213-2600(22)00504-5
LANCET RESPIRATORY MEDICINE
Background: Elexacaftor–tezacaftor–ivacaftor has been shown to be safe and efficacious in people with cystic fibrosis and at least one F508del allele. Our aim was to identify a novel cystic fibrosis transmembrane conductance regulator (CFTR) modu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b19fd4ef9823a3f92122d18b15dec4
https://research.vumc.nl/en/publications/0a8b171c-28b7-4da9-8e4a-5749733cacf9
https://research.vumc.nl/en/publications/0a8b171c-28b7-4da9-8e4a-5749733cacf9
Autor:
India, Loyd, Nicole, Papac, Jason, Hirshburg, Jarad, Levin, Jennifer, Dannelley, Janislynn, Dorris, Jason, Stratton, Nighat, Mehdi
Publikováno v:
J Pediatr Pharmacol Ther
Adverse reactions, including severe cutaneous reactions, to cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been described in the literature. Herein we present a drug eruption in response to elexacaftor/tezcaftor/ivacaftor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1fb29728ccfbf21291ef8570feb7f10
https://doi.org/10.5863/1551-6776-27.5.467
https://doi.org/10.5863/1551-6776-27.5.467
Autor:
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, Gregory S Sawicki, Philip Chang, Hildegarde Paz-Diaz, Jaime L Rubin, Yoojung Yang, Xingdi Hu, David J Pasta, Stefanie J Millar, Daniel Campbell, Xin Wang, Neil Ahluwalia, Caroline A Owen, Claire E Wainwright, Ronald L. Gibson, Steven M. Rowe, Noah Lechtzin, Richard C. Ahrens, Karen S. McCoy, Moira Aitken, Scott H. Donaldson, Kimberly Ann McBennett, Joseph M. Pilewski, Joanne Billings, Carlos Milla, Ronald Rubenstein, Daniel Brian Rosenbluth, Rachel Linnemann, Michael R. Powers, Christopher Fortner, Carla Anne Frederick, Theodore G. Liou, Philip Black, Janice Wang, John L. Colombo, Maria Berdella, Maria Veronica Indihar, Cynthia D. Brown, Michael Anstead, Lara Bilodeau, Leonard Sicilian, James Jerome Tolle, Kathryn Moffett, Samya Nasr, Jennifer Taylor-Cousar, Tara Lynn Barto, Nicholas Antos, John S. Rogers, Bryon Quick, Henry R. Thompson, Gregory Sawicki, Bruce Barnett, Robert L. Zanni, Thomas C. Smith, Karen D. Schultz, Claire Keating, Patrick Flume, Gregory J. Omlor, Alix Ashare, Karen Voter, Nighat Mehdi, Maria Gabriela Tupayachi Ortiz, Tonia E. Gardner, Steven R. Boas, Barbara Messore, Edith Zemanick, Raksha Jain, Michael McCarthy, Dana G. Kissner, Kapilkumar Patel, John McNamara, Julie Philley, Ariel Berlinski, Francisco J. Calimano, Terry Chin, Douglas Conrad, Cori Daines, Hengameh H. Raissy, Thomas G. Keens, Jorge E. Lascano, Bennie McWilliams, Brian Morrissey, Santiago Reyes, Subramanyam Chittivelu, Sabiha Hussain, Arvey Stone, James Wallace, Ross Klingsberg, Julie A. Biller, Stephanie Bui, Olaf Sommerburg, Elisabetta Bignamini, Mirella Collura, Alexander Moller, Donatello Salvatore, Chantal Belleguic, Lea Bentur, Ori Efrati, Eitan Kerem, Dario Prais, Esther Quintana Gallego, Peter Barry, Galit Livnat-Levanon, Jose Ramon Villa Asensi, David Stuart Armstrong, Oscar Asensio de la Cruz, Francis Gilchrist, Diana Elizabeth Tullis, Bradley Quon, Larry C. Lands, Nancy Morrison, Annick Lavoie, Barry Linnane, Okan Elidemir, Felix Ringshausen, Matthias Kappler, Helge Hebestreit, Jochen Mainz, Alexander Kiefer, Cordula Koerner-Rettberg, Doris Staab, Wolfgang Gleiber, Tacjana Pressler, Florian Stehling, Andreas Hector, Sivagurunathan Sutharsan, Lutz Naehrlich, Damian Downey, Jane Carolyn Davies, Robert Ian Ketchell, Mary Patricia Carroll, Simon Doe, Gordon MacGregor, Edward Fairbairn Nash, Nicholas Withers, Daniel Gavin Peckham, Martin James Ledson, Sonal Kansra, Timothy William Rayner Lee, Bertrand Delaisi, Gilles Rault, Jean Le Bihan, Dominique Hubert, Isabelle Fajac, Isabelle Sermet-Gaudelus, Marleen Bakker, Bert Arets, Christiane De Boeck, Raphael Chiron, Philippe Reix, Catherine Mainguy, Eva van Braeckel, Anne Malfroot, Isabelle Durieu, Nadine Desmazes Dufeu, Anne Prevotat, Renske van der Meer, Petrus Merkus, E.J.M. Weersink, Isabel Barrio Gomez-Aguero, Silvia Gartner, Amparo Sole Jover, Antonio Alvarez Fernandez, Desmond William Cox, Edward F. McKone, Barry James Plant, Hiranjan Selvadurai, Simon David Bowler, Claire Elizabeth Wainwright, Daniel Smith, Peter Gordon Middleton, John William Wilson, Sonia Volpi, Carla Colombo, Benedetta Fabrizzi, Vincenzina Lucidi, Federico Cresta, Salvatore Cucchiara, Ernst Eber, Helmut Ellemunter, Isidor Huttegger, Lena Hjelte, Christina Krantz, Marita Gilljam
Publikováno v:
lancet. Respiratory medicine, 9(7), 733-746. Elsevier Limited
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
Summary Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8–24 weeks in phase 3 clinical studies in participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf49af3de3f90b3a65bf102dbba3756b
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e25362cf07bd88d1d3728962d9a50
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
Autor:
Cara Nwankwo, Alexandra L Blair, Nighat Mehdi, Nicole M Ruppe, Ashley H. Clawson, Marissa N Baudino
Publikováno v:
Handbook of Cognitive Behavioral Therapy for Pediatric Medical Conditions ISBN: 9783030216825
Asthma is the most prevalent chronic medical condition among youth. Youth with asthma have higher rates of anxiety, depression, behavioral difficulties, and similar or higher rates of engaging in deleterious health behaviors (e.g., tobacco and mariju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8806e111b3d8934da46aa45ac93cd8b3
https://doi.org/10.1007/978-3-030-21683-2_22
https://doi.org/10.1007/978-3-030-21683-2_22
Autor:
Nighat Mehdi, Victoria Mcmeen
Publikováno v:
Pediatric Asthma, Allergy & Immunology. 19:180-184
The management of pediatric bronchial asthma is often addressed by emergency department (ED) personnel. By surveying emergency program directors, we identify prevailing methods of albuterol delivery for the treatment of an acute asthma exacerbation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68dcb14f7f29ff9079702dd37bdf7232
https://doi.org/10.1089/pai.2006.19.180
https://doi.org/10.1089/pai.2006.19.180
Publikováno v:
Pediatric Asthma, Allergy & Immunology. 18:55-61
Chronic cough in children represents a diagnostic challenge. This study evaluates the outcomes of a simple diagnostic approach that uses a positive response to therapeutic trial of asthma with short course of oral steroids as a diagnostic test if his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7d0ddad80cc552eefd229907d0aac70
https://doi.org/10.1089/pai.2005.18.55
https://doi.org/10.1089/pai.2005.18.55
Publikováno v:
Archives of Pediatrics & Adolescent Medicine. 156:81
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aacadd9648afc101b807d3358cfb899
https://doi.org/10.1001/archpedi.156.1.81
https://doi.org/10.1001/archpedi.156.1.81
Publikováno v:
Pediatric Asthma, Allergy & Immunology; Summer2005, Vol. 18 Issue 2, p55-61, 7p